



MEDBOT™
微创机器人



2025 Interim Results Presentation

September 2025

Disclaimer

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of Shanghai MicroPort MedBot (Group) Co., Ltd., and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

FORWARD-LOOKING STATEMENTS

Some information contained in this presentation contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe”, “intend”, “expect”, “anticipate”, “project”, “estimate”, “predict”, “is confident”, “has confidence” and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MedBot’s management and are subject to significant risks and uncertainties. of Shanghai MicroPort MedBot (Group) Co., Ltd. undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China and other countries that of Shanghai MicroPort MedBot (Group) Co., Ltd. operates in.

CONFIDENTIALITY

This presentation is confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose.

AGENDA

- 
- ▶ **Business Highlights**
 - Product Pipeline Update**
 - Financial Review**
 - Appendix**

Key Business Highlights

Net loss **115mn**
 Narrowed **59%** YoY

FCF **135mn**
 Improved **43%** YoY

Overseas
 market sales:
 103mn,
 +189% YoY

176mn
 Sales (RMB)
 +**77%** YoY



150+ orders
100+ installed
 accumulatively for our
 product portfolio



~90
 Toumai

~60
 SkyWalker

7
 R-ONE

30+
 new overseas orders
 received YTD

16
 units installed in
 overseas market in 1H25

50+



Orders received
 in Toumai®'s
 overseas exploration



~500
 Remote surgeries
 completed by Toumai®

1st
 globally approved remote
 surgical robot - NMPA
 approval obtained

1st
 FDA-IDE approved remote
 surgery globally


12,000+
 surgeries completed
 up to date by Toumai®

1,000
 cases by single
 center as the
 highest up to date

>10%
 of Toumai's 1H25 revenue
 contributed by sales of
 instrument & accessories

Revenue Strides Ignited by Robust Global Market Momentum

(RMB mn)



Toumai®



No.1 among domestic brands in terms of orders and installation base

- **Accumulated ~90 units of orders** received globally, covering 4 major continents - Europe, Asia, Africa and Latin America
 - ✓ **50+ orders** from overseas market (incl. **30+ new orders** received YTD in 2025)
- **22 units of new installation** in 1H25, giving a total of **60+ units** of global installation base to date
- **>10%** of revenue from **sales of instruments & accessories**

SkyWalker™



- **10+ units** of new orders, mainly from developed countries, **~60 units** of orders accumulatively
- **8 unit of new installation** on leverage of synergies with MicroPort Group orthopedic business, **accumulatively 35 units** globally

R-ONE®




- Achieved **5 units** of commercialized installation in the top public hospitals at Shanghai

Well-established and Widely-recognized Global Market Presence

SRS2025: Highly recognized by global KOLs



Global Installation Base
(commercialized, by Jun 30, 2025)




China:	36	China:	8
Overseas:	27	Overseas:	27



 More products with overseas regulatory approvals

 Synergy with MicroPort for global commercialization

 Increased academic influence on an international scale

 Recognition from experts around the world

Demonstration of Leading Edge and Clinical Competency through Large-scale surgeries



Surgical procedures

Toumai®

- ✓ Maintained **No.1** in terms of clinical operations among domestic brands
- ✓ Completed **12,000+** clinical surgeries up to date

SkyWalker™

- ✓ Assisted with **~2,500** TKA procedures accumulatively
- ✓ Covered **75** hospitals in China and **25** hospitals in Europe and US.



Surgeons training

Toumai®

- ✓ **~40** training centers globally
- ✓ Established **5 overseas training centers**
- ✓ **~800 training sessions** held in 1H25

Case studies



Shanghai Pulmonary Hospital

Toumai® assisted in 1,000+ surgeries



Professor Zhang Xuepei from the First Affiliated Hospital of Zhengzhou University
Personal robotic surgery 200+ cases



MMT hospital in Georgia

Completed 200+ cases
RALRP in <1H30mins



Toumai® in Morocco

Completed 320+ operations
in 12 months



Doctors Hospital & Medical Center in Pakistan

Completed 100+ cases
in 10 weeks

World's 1st Approval – Ushering the Surgical Robot Industry into the Remote Era

April 2025

Ruijin Hospital - A five-location remote surgery conducted for patients in Sanming (Fujian), Diqing (Yunnan), Ruijin (Jiangxi), Boao (Hainan) and Jiading (Shanghai)

May 2025

European 1st remote surgery conducted successfully in Belgium with assistance from Toumai®

June 2025

The world's **1st FDA IDE-approved** clinical remote tele-surgery trial conducted, RALRP from Orlando Florida (USA), to Luanda (Angola)

The world's 1st
remote surgical robot
to be approved

Dec 2024 & July 2025

World's 1st satellite-based robotic telesurgery and the first remote surgery performed via low Earth orbit (LEO) satellite

July 2025

World's 1st transcontinental ultra-long-distance robot-assisted liver cancer resection surgery, on SRS 2025

July 2025

1st Transcontinental Ultra-Remote Prostatectomy from Europe to Middel East, on SRS 2025

~500

Complex remote
surgeries

100%

Surgery
success rate

50+

National/
world records

103

Countries/regions
229
Cities

465

Hospitals/centers

1,000,000+km

Accumulative
transmission distance

Business Highlights

Multiple Flagship Products Gained Global Market Access

Toumai®

Obtained 10+ new registration approvals in 1H25


30+ countries/regions approved in total



Toumai® Single-port

Approved by **NMPA** in Feb 2025

Approved by MOHAP (UAE)



Toumai® Remote

Obtained NMPA approval in April 2025

The world's 1st approval for remote surgical robot



SkyWalker™

Obtained CE mark for THA Application


10 countries/ regions approvals in total



Improved Operational Effectiveness on Stringent Cost-optimization Strategies


Gross profit

(RMB million)




Optimizing Operational Efficiency

(RMB million)




Net Loss Narrowed

(RMB million)



Free Cash Outflow Decreased

(RMB million)



AGENDA

Business Highlights

▶ **Product Pipeline Update**

Financial Review

Appendix

Product Pipeline Update

Comprehensive product offering covering all 5 major and fast-growing surgical specialties

		Medical Device					
Surgical Specialty	Product	Indicated Application	Product Classification	Design Development	Design Validation	Clinical Trial/ Clinical Evaluation	Registration Application
Self-development	Laparoscopic Surgery	Toumai® (图迈®) Laparoscopic Surgical Robot	Urologic surgery	III (Green Path)			
			Gynecologic surgery	IIb (CE)			
			Thoracic surgery				
			General surgery				
		Toumai® (图迈®) Remote Laparoscopic Surgical Robot	Urologic, Gynecologic, Thoracic and General Surgery	III			
		Toumai® (图迈®) Single-port Laparoscopic Surgical Robot	Urologic, Gynecologic and General Surgery	III			
	Orthopedic Surgery	DFVision® (蜻蜓眼®) 3D Electronic Laparoscope	Laparoscopy (fluorescence imaging function)	II (Green Path)			
				IIa (CE)			
				II (FDA)			
		SkyWalker™ (鸿鹄®) Orthopedic Surgical Robot	Total knee arthroplasty	IIb (CE)			
				III (Green Path)			
			Total hip arthroplasty	III			
				IIb (CE)			
				III			
	Natural Orifice Surgery	Trans-bronchial Surgical Robot	Trans-bronchial diagnosis & treatment	III			
International collaboration	Panvascular Surgery	R-ONE® Panvascular Surgical Robot	Coronary angioplasty	III			
	Percutaneous Surgery	iSR'obot® Mona Lisa Robotic Transperineal Prostate Biopsy System	Transperineal prostate biopsy	III			

Note:

1. Approved in 30+ countries/regions, incl. Brazil, Ecuador, Taiwan, Malaysia, Thailand, Philippines, Morocco, South Africa, Türkiye, Jordan, Serbia, Uzbekistan, Belarus, Switzerland, UK etc

2. Approved in Brazil, Australia, India, Japan, UK, Canada, Thailand

NMPA approval FDA / CE approval Other regions' approval

Flagship product– Toumai® Laparoscopic Surgical Robot



Pioneer in domestic brands

Domestic Leader with premium quality demonstrated in large-scale clinical validation

- Maintained **leading position, #1 market share** among domestic brands with ramped up winning bids and commercial installation:
 - 22 units** of new commercial installation in 1H25
 - 60+ units** of commercial installation base to date
- Comprehensive Total Solution for hospitals: **Multi-port + Single-port + Tele-surgery**
- Large volume surgery: **12,000+ cases, No.1 among domestic brands**



Globalization Footprint

Commercialization breakthrough

- Obtained **30+ units of new order in 2025 YTD**
- Achieved **16 units of overseas commercial installation in 1H25**, accumulated 27 units of commercial installation.
- Established **5 overseas training centers**, e.g. ORSI Academy (Belgium), IRCAD (France)

Regulation approval milestone

- 1st and only Chinese laparoscopic surgical robot with **CE mark**
- Obtained registration approvals in **30+ countries/regions**

Increased overseas influence

- SRS 2025** – 26 academic events, 3 live/record remote surgery broadcasts, 22 speeches




#1 Remote Surgical Robot

Leading global surgical robot into the Remote Era

- Obtained the world's **1st registration approval for remote surgical robot**
- ~500** remote clinical surgeries, 100% success rate, created **over 50** records of 1st remote surgery in China and globally
- 1st and only intercontinental remote surgery network**, connecting 465 centers, 229 cities in 103 countries/regions
- Initiated the 3rd generation of remote surgery technology – **Robotic satellite remote surgery**
- Completed the world's **1st remote surgery approved by FDA-IDE**, from US to Angola

Multiple generations of Toumai® clinical progress



Flagship product – SkyWalker™ Orthopedic Surgical Robot

The 1st domestic surgical robot to expand into global market

2022

China (NMPA)
US (FDA)
Europe (CE)

2023

China (NMPA, THA)
Brazil
Australia

2024

India
Japan
UK
Canada

2025

Europe (CE, THA)
Thailand
More to expect...

Continued decent global commercialization trend

- ~60 orders in total up to date
- 10+ new orders received in 1H25
- 35 units of global installation base
- (8 new installed units in 1H25)
- Clinical operations expanded to 100+ hospitals in China and abroad
- One of the six orthopedic surgical robots recommended by NICE UK



Providing complete clinical total solution



1



1



2



- **Evolution™ medial-pivot knee**
A legacy of 98.8% survivorship and 17 years and 95% patient satisfaction
- **SuperPATH® hip approach**
Enables a faster recovery for patients after THA surgeries

**Better joint replacement
surgical total solution**

Steady upgrade in product capability



RA-TKA for sever
deformity



Precise RA bone
tumor operation



Efficiency
orthopedics + AI



Remote surgery
orthopedics + 5G

Natural Orifice Surgical Robot



Robot-assisted natural orifice surgery

Surgery application

- Natural orifice surgical robots refer to robots that deliver surgical instruments to the target anatomy through natural pathways of the human body and control them for diagnosis or surgery
- Natural orifice surgical robots are applied in natural orifice transluminal laparoscopic surgeries, such as



Bronchoscopy
(examination of
the lungs)



Colonoscopy
(examination of
the bowel)



Gastroscopy
(examination of
the stomach)



Product



Features /
Technology



Indication
application



Clinical status

Trans-bronchial Surgical Robot



- Leverage the power of flexible robotics which uses a camera and tools to enter the lungs through their natural airways
- Precisely guide a biopsy instrument to those hard-to-reach nodules

Trans-bronchial diagnosis and treatment

- In the process of NMPA application, **expected to obtain approval in 2025E**
- **World's 1st 5G Remote "Autonomous Driving" Robotic Bronchoscopic Cryoablation** animal study



R-ONE® Vascular Interventional Robot System



NMPA approval

CE mark



Designed to operate with precision and perform specific movements



Facilitate and enhance the interventional procedures performed on the patient

Clinical Performance & Leading 5G Application

July 2023

Completed first 5G tele-robot PCI operation in human across 2800 km

Feburery 2024

Headlines made on Bangladesh's national news successful tele-robot PCI operation on complex cases

Up to date

Completed **100+** PCI operations and **20+** remote procedures

Strong Commercialization Momentum



- **5 units** of new installation in 1H25, for five top Grade IIIA hospitals in Shanghai, accumulatively 7 units installed



- The rapid commercialization process reflects **good product performance and great market potential**

Unique Synergy advantages



- Synergy with the cardiovascular business of MicroPort Group
- Which will substantially facilitate the commercialization of R-ONE®



- Leading application of tele-robot remote PCI operation

Mona Lisa Robotic Transperineal Prostate Biopsy System



NMPA Approval
FDA Approval
CE Marking
TGA Approval
HAS Approval



Real-time ultrasound images displayed on the monitor during the biopsy procedure



The surgeon manually inserts the needle into the prostate to collect the biopsy cores

Unique Competing Advantage



1st commercially placement in 2023



Obtained NMPA approval in May 2023
- 1st transperineal prostate biopsy robot certified in the field of urology in China



Leading technology

- Accurate and efficient conduction
- Improve the positive detection rate
- Reduce manual error and omission

Unmet Market Demand



Prostate biopsy market demand



Transperineal prostate biopsy¹



More than 20,000 clinical applications worldwide

Note: ¹ A diagnostic procedure in which the surgeon passes the biopsy needle through the perineal skin and into the prostate

Unique Synergy Advantages



To cooperate with Toumai®, providing integrated diagnose and treatment solutions in urology



1st prostate cancer treatment globally through combination of prostate biopsy surgical robot and cryoablation platform

Prostate biopsy surgical robot




Cryoablation platform



南京鼓楼醫院
南京大学医学院附属鼓楼醫院
Nanjing Drum Tower Hospital

Strong industrial operation capabilities for surgical robots



AGENDA

Business Highlights

Product Pipeline Update

▶ Financial Review

Appendix

Consolidated Financial Performance


REVENUE

Total revenue reached 175.7m with a growth rate of 77%, mainly attributable to the rapid commercial expansion of multiple products, especially a significant 189% growth in revenue from overseas markets.

The core product, Toumai®, continued to maintain strong growth momentum, particularly with overseas markets becoming the core growth engine. Additionally, SkyWalker Orthopedic Robot has expanded into emerging regions, and R-ONE has gained market recognition since its launch, both of which are experiencing steady growth.

New products and new market

(RMB million)




TOTAL NET LOSS

Total net loss decreased from 280.0m for the six months ended 30 June 2024 to 114.9m for the current period. The adjusted net loss also decreased to 97.1m. The great decrease was mainly contributed by (i) the rapid growth in revenue; and (ii) the comprehensive implementation of strategic focus and various measures to reduce costs and increase efficiency since 2023, which has resulted in a significant decrease in operating expenses

Productivity improvement

(RMB million)




* Adjusted net loss as a non-HKFRS measure has eliminated potential impacts of certain items that do not affect our ongoing operating performance,

FREE CASH FLOW

The success of revenue growth, costs reduction and operation efficiency led to a great decrease in net free cash outflow.

Cash-flow management


(RMB million)



Operating Expenses

R&D COST

(RMB million)




R&D 88.6m, 46% decline YoY

The decrease was primarily due to the fact that the core product Toumai and the flagship product SkyWalker have achieved phased results. Meanwhile, the Company focuses on the product pipeline near/at the stage of commercialization and the improvement on R&D efficiency.

S&M EXPENSES

(RMB million)




S&M 80.4m, 13% decline YoY and supporting 77% growth of revenue

The proportion of revenue dropped significantly to 46% in the Reporting Period. Promotion efficiency in domestic market has been enhanced. Meanwhile, overseas investment increased slightly, benefiting from the synergistic effects with the sales networks of affiliated companies.

ADMINISTRATIVE EXPENSES

(RMB million)



G&A 18.1m, decreased by 40% YoY

Continuously improved operational efficiency

In Closing



We **delivered record revenue** and robust momentum to drive continuous growth



We enjoy large, **global market opportunities**



Our comprehensive product pipeline **enables** technology integration, **stimulates** sales synergy, and **provides** integrated diagnostic and treatment solutions



We are **positioned for financial improvement** based on the good foundation established by our cost reduction and efficiency improvement initiatives



Our premium product quality, innovation ability **earned the trust of our clients and industry experts**

AGENDA

Business Highlights

Product Pipeline Update

Financial Review

▶ Appendix

Appendix I - Consolidated Balance Sheet

Unit: RMB'000	30 Jun 2025	31 Dec 2024	Var.
Non-current assets			
Property, plant and equipment	251,102	297,371	-16%
Intangible assets	2,733	3,972	-31%
Goodwill	1,482	1,482	0%
Trade receivables	1,940	2,579	
Equity-accounted investees	18,781	11,887	58%
Financial assets measured at FVPL	71,329	67,054	6%
Other non-current assets	39,043	38,148	2%
Total Non-current assets	386,410	422,493	-9%
Current assets			
Inventories	159,833	151,481	6%
Trade and other receivables	137,757	92,835	48%
Cash and cash equivalents	815,790	612,230	33%
Total Current assets	1,113,380	856,546	30%
Current liabilities			
Interest-bearing borrowings	416,258	245,223	70%
Trade and other payables	182,400	201,476	-9%
Contract liabilities	12,332	8,718	41%
Lease liabilities	30,047	34,511	-13%
Provisions	17,470	13,529	29%
Total Current liabilities	658,507	503,457	31%
Non-current liabilities			
Interest-bearing borrowings	216,700	389,312	-44%
Lease liabilities	5,216	22,281	-77%
Deferred income	91,183	93,147	-2%
Contract liabilities	13,925	12,527	11%
Provisions	412	637	-35%
Total Non-current liabilities	327,436	517,904	-37%
NET ASSETS	513,847	257,678	99%

Unit: RMB'000	30 Jun 2025	31 Dec 2024	Var.
CAPITAL AND RESERVES			
Share capital	1,031,330	1,006,194	2%
Reserves	(496,224)	(727,992)	-32%
Total equity attributable to equity shareholders of the Company	535,106	278,202	92%
Non-controlling interests	(21,259)	(20,524)	4%
TOTAL EQUITY	513,847	257,678	99%

Appendix II - Consolidated P&L

Unit: RMB'000	30 Jun 2025	30 Jun 2024	Var.
Revenue	175,689	99,237	77%
Cost of sales	(104,183)	(52,224)	99%
Gross profit	71,506	47,013	52%
Other net income	519	5,298	-90%
Selling and marketing expenses	(80,411)	(92,223)	-13%
Administrative expenses	(18,055)	(30,072)	-40%
Research and development costs	(88,614)	(164,149)	-46%
Net gain/(loss) on financial instruments carried at fair value through profit or loss (FVPL)	4,275	(10,443)	-141%
Loss from operations	(110,780)	(244,576)	-55%
Finance costs	(11,023)	(9,834)	12%
Share of losses of equity-accounted investees	3,012	(9,843)	-131%
Reversal of/(provision for) impairment loss on an equity-accounted investee	3,868	(15,697)	-125%
Loss before taxation	(114,923)	(279,950)	-59%
Income tax	-	-	
Loss for the year	(114,923)	(279,950)	-59%
Attributable to:			
Equity shareholders of the Company	(113,351)	(277,161)	-59%
Non-controlling interests	(1,572)	(2,789)	-44%
Loss for the year	(114,923)	(279,950)	-59%
Loss per share (RMB)			
Basic and diluted (RMB)	(0.11)	(0.29)	-62%



MEDBOT™
微创机器人



THANK YOU



微创机器人
(服务号)



MedBot Surgical
(订阅号)